文献速递白血病造血干细胞移植与细胞治疗

自体与无关供者造血干细胞移植治疗成人原发性急性髓系白血病首次完全缓解期的比较

[Autologous versus unrelated donor stem cell transplantation for adults with primary acute myeloid leukemia in first remission].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

单中心回顾性研究纳入2008年3月至2018年11月147例成人原发性AML-CR1患者(auto-HSCT组87例,URD-HSCT组60例),两组5年OS率和LFS率无显著差异,auto-HSCT组复发率较高而移植相关死亡率较低;遗传学高危患者auto-HSCT后复发率更高、LFS率更低。

要点

  • auto-HSCT与URD-HSCT的5年OS率和LFS率无显著差异。
  • auto-HSCT组5年累积复发率高于URD-HSCT组,TRM低于URD-HSCT组。
  • 遗传学高危患者auto-HSCT后复发率更高、LFS率更低。

核心结论

  • 成人原发性AML-CR1患者auto-HSCT后复发率较高但TRM较低,生存与URD-HSCT相当。
  • 缺乏同胞供者的遗传学高危患者应选择URD-HSCT以减少移植后复发、提高生存率。

研究设计与样本

  • 单中心回顾性研究,纳入2008年3月至2018年11月接受auto-HSCT或URD-HSCT的成人原发性AML患者147例(auto-HSCT组87例,URD-HSCT组60例)。

主要发现

  • +30天粒细胞累积植活率两组差异无统计学意义[auto-HSCT组92.6%(95%CI 86.9%-98.3%)vs URD-HSCT组98.3%(95%CI 95.0%-100.0%),P=0.270]。
  • auto-HSCT组+60天血小板累积植活率低于URD-HSCT组[83.6%(95%CI 75.8%-91.4%)vs 93.3%(95%CI 87.0%-99.6%),P<0.001]。
  • URD-HSCT组急性GVHD累积发生率56.7%(95%CI 43.0%-68.2%),Ⅱ~Ⅳ度急性GVHD累积发生率16.7%(95%CI 8.5%-27.2%),慢性GVHD累积发生率33.3%(95%CI 21.7%-45.4%),广泛型慢性GVHD累积发生率15.0%(95%CI 7.3%-25.2%)。
  • 中位随访53.8(0.8-127.8)个月,auto-HSCT组与URD-HSCT组5年OS率分别为71.7%(95%CI 61.7%-81.7%)与67.8%(95%CI 55.8%-79.8%)(P=0.556),5年LFS率分别为64.6%(95%CI 54.4%-74.8%)与68.1%(95%CI 56.3%-79.9%)(P=0.642)。
  • auto-HSCT组5年累积复发率高于URD-HSCT组[31.9%(95%CI 22.2%-42.1%)vs 15.1%(95%CI 7.4%-25.6%),P=0.015],TRM低于URD-HSCT组[3.4%(95%CI 0.9%-8.9%)vs 16.7%(95%CI 8.5%-27.2%),P=0.006]。

关键数值与推荐

  • HLA相合与不全相合的无关供者移植在造血重建、GVHD、OS、LFS、复发及TRM方面差异均无统计学意义。
  • 遗传学低、中危患者auto-HSCT与URD-HSCT后OS率、LFS率差异均无统计学意义。
  • 遗传学高危患者auto-HSCT后累积复发率高于URD-HSCT,LFS率低于URD-HSCT。

临床怎么用

  • 缺乏同胞供者的遗传学高危成人原发性AML-CR1患者应选择URD-HSCT以减少移植后复发、提高生存率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare differences of autologous and unrelated donor stem cell transplantation (auto-HSCT and URD-HSCT) for adults with primary acute myeloid leukemia (AML) in first complete remission (CR(1)) from a single center and to investigate the appropriate patients for the 2 types of transplant. Methods: In this retrospective investigation, we studied adults with primary AML who received auto-HSCT and URD-HSCT from March 2008 to November 2018. Overall survival (OS) , leukemia-free survival (LFS) , relapse, transplant-related mortality (TRM) , and hematopoietic reconstitution were compared along with the prognostic value of cytogenetics. Results: A total of 147 adult patients were enrolled in this study (n=87 for auto-HSCT and n=60 for URD-HSCT) . Baseline characteristics were comparable between the 2 groups. The accumulative neutrophil engraftment rate at +30 days was not statistically different between the 2 groups[92.6% (95% CI 86.9%-98.3%) vs 98.3% (95% CI 95.0%-100.0%) , P=0.270], whereas the accumulative platelet engraftment rate at +60 days was significantly lower in the auto-HSCT group[83.6% (95% CI 75.8%-91.4%) vs 93.3% (95% CI 87.0%-99.6%) , P<0.001]. In patients undergoing URD-HSCT, the accumulative incidences of acute GVHD (aGVHD) and grade Ⅱ-Ⅳ aGVHD were 56.7% (95% CI 43.0%-68.2%) and 16.7% (95% CI 8.5%-27.2%) , and the incidences of chronic GVHD (cGVHD) and extensive cGVHD were 33.3% (95% CI 21.7%-45.4%) and 15.0% (95% CI 7.3%-25.2%) , respectively. After a median follow-up of 53.8 (0.8-127.8) months, patients in the 2 groups demonstrated comparable OS and LFS at 5 years after transplant[71.7% (95% CI 61.7%-81.7%) vs 67.8% (95% CI 55.8%-79.8%) , P=0.556; 64.6% (95% CI 54.4%-74.8%) vs 68.1% (95% CI 56.3%-79.9%) , P=0.642]. Patients in the auto-HSCT group showed significantly higher incidence of relapse at 5 years after transplant[31.9% (95% CI 22.2%-42.1%) vs 15.1% (95% CI 7.4%-25.6%) , P=0.015] and significantly lower incidence of TRM[3.4% (95% CI 0.9%-8.9%) vs 16.7% (95% CI 8.5%-27.2%) , P=0.006] compared with the URD group. HLA mismatching had no effects on the incidences of hematopoietic reconstitution, GVHD, OS, LFS, relapse, and TRM. Patients of cytogenetically favorable and intermediate risk demonstrated comparable OS and LFS after auto-HSCT and URD-HSCT, while patients of poor risk had significantly higher relapse and lower LFS after auto-HSCT. Conclusions: In this study, adults with primary AML in CR(1) demonstrated relatively higher relapse but lower TRM after auto-HSCT, resulting in comparable survival to that of URD-HSCT. In the absence of matched sibling donors, patients of cytogenetically poor risk should receive URD-HSCT in order to achieve lower relapse and better survival. 目的: 分析自体造血干细胞移植(auto-HSCT)与无关供者造血干细胞移植(URD-HSCT)治疗首次完全缓解期(CR(1))成人原发性急性髓系白血病(AML)的疗效,比较并探讨两种移植方式的差异及适应人群。 方法: 对2008年3月至2018年11月在中国医学科学院血液病医院接受auto-HSCT及URD-HSCT的成人原发性AML患者进行回顾性分析。 结果: 共纳入147例患者,其中auto-HSCT组87例,URD-HSCT组60例,两组病例基线特征基本一致。auto-HSCT组、URD-HSCT组+30 d粒细胞植活率差异无统计学意义[92.6%(95% CI 86.9%~98.3%)对98.3%(95% CI 95.0%~100.0%),P=0.270],auto-HSCT组+60 d血小板累积植活率低于URD-HSCT组[83.6%(95% CI 75.8%~91.4%)对93.3%(95% CI 87.0%~99.6%),P<0.001]。URD-HSCT组急性GVHD累积发生率为56.7%(95% CI 43.0%~68.2%),Ⅱ~Ⅳ度急性GVHD累积发生率为16.7%(95% CI 8.5%~27.2%),慢性GVHD累积发生率为33.3%(95% CI 21.7%~45.4%),广泛型慢性GVHD累积发生率为15.0%(95% CI 7.3%~25.2%)。中位随访53.8(0.8~127.8)个月,auto-HSCT组、URD-HSCT组5年总生存(OS)率分别为71.7%(95% CI 61.7%~81.7%)、67.8%(95% CI 55.8%~79.8%)(P=0.556),无白血病生存(LFS)率分别为64.6%(95% CI 54.4%~74.8%)、68.1%(95% CI 56.3%~79.9%)(P=0.642)。auto-HSCT组5年累积复发率高于URD-HSCT组[31.9%(95% CI 22.2%~42.1%)对15.1%(95% CI 7.4%~25.6%),P=0.015],移植相关死亡率(TRM)低于URD-HSCT组[3.4%(95% CI 0.9%~8.9%)对16.7%(95% CI 8.5%~27.2%),P=0.006]。HLA相合及不全相合的无关供者移植在造血重建、GVHD、OS、LFS、复发及TRM方面差异均无统计学意义。遗传学低、中危患者auto-HSCT、URD-HSCT组移植后OS率、LFS率差异均无统计学意义,高危患者auto-HSCT后累积复发率高于URD-HSCT,LFS率低于URD-HSCT。 结论: 对于成人原发性AML-CR(1)患者,auto-HSCT与URD-HSCT具有相似的OS率和LFS率,auto-HSCT组复发率较高而TRM较低。缺乏同胞供者的遗传学高危组患者应选择URD-HSCT以减少移植后复发,提高生存率。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yao JF, Zhang GX, Yang DL, et al. [Autologous versus unrelated donor stem cell transplantation for adults with primary acute myeloid leukemia in first remission]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32536132. doi:10.3760/cma.j.issn.0253-2727.2020.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。